Please assess the completion status of the following clinical trial:

Trial Title: Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age; greater than 12 years old and able to cooperate for full study protocol~* Subject able to understand and sign informed consent~* Subject able to participate in complete ophthalmic and ocular motility evaluation~* Subjects with Infantile Nystagmus Syndrome diagnosed by clinical evaluation and eye movement recordings~* Best-binocular visual acuity in null position 20/50 to 20/200 inclusive using ATS or ETDRS vision testing~* Subject/family able and willing to make the required study visits~* No previous ophthalmic treatment for nystagmus other than for refractive error~Exclusion Criteria:~* Any current use of systemic or topical medications (traditional or non-traditional)~* History of ocular surgery, trauma or chronic ocular disease other than amblyopia~* Systemic diseases requiring medication or other treatments that are known to affect the ocular motor system (e.g., depression, seizure disorders, psychosis)~* Behavioral or neurological disorders which interfere with the study~* Physical or mental impairment precluding study compliance~* Participation in any study involving an IND investigational drug within the past year~* Individual (female) is pregnant, nursing or planning a pregnancy (The safety of Azopt for use during pregnancy has NOT been determined.)~* Periodicity or aperiodicity of INS present on eye movement recordings~* Allergy to sulfa or other components of Azopt solution

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topical Brinzolamide (Azopt) (Type: ACTIVE_COMPARATOR): ophthalmic drop given three times a day
- placebo ophthalmic drop in 5 mL solution (Type: PLACEBO_COMPARATOR): masked non-active eye drop (absence of Brinzolamide)

Based on this trial design, predict the completion outcome and termination type (if applicable).